Repare Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Repare Therapeutics's estimated annual revenue is currently $25.9M per year.
- Repare Therapeutics's estimated revenue per employee is $143,011
- Repare Therapeutics's total funding is $150.5M.
- Repare Therapeutics's current valuation is $635.6M. (January 2022)
Employee Data
- Repare Therapeutics has 181 Employees.
- Repare Therapeutics grew their employee count by 3% last year.
Repare Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $25.9M | 181 | 3% | $150.5M | N/A |
#2 | $28.4M | 183 | -56% | N/A | N/A |
#3 | $4.3M | 28 | 8% | N/A | N/A |
#4 | $55.6M | 359 | 1% | N/A | N/A |
#5 | $11M | 71 | 20% | N/A | N/A |
#6 | $22.2M | 143 | -22% | N/A | N/A |
#7 | $4.2M | 27 | 13% | N/A | N/A |
#8 | $2M | 13 | 0% | N/A | N/A |
#9 | $295.7M | 1908 | 5% | N/A | N/A |
#10 | $2.8M | 18 | 6% | N/A | N/A |
What Is Repare Therapeutics?
Repare Therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. Repare's platform combines a proprietary, high throughput, CRISPRâ€enabled gene editing target discovery method with highâ€resolution protein crystallography, computational biology and clinical informatics. The company is backed by leading global healthcare investors including founding investor Versant Ventures and MPM Capital. For additional information, please visit www.reparerx.com.
keywords:N/A
$150.5M
Total Funding
181
Number of Employees
$25.9M
Revenue (est)
3%
Employee Growth %
$635.6M
Valuation
N/A
Accelerator
Repare Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Director Pharmacology | Reveal Email/Phone |
2 | Director | Reveal Email/Phone |
3 | Director (2022-present) / Associate Director (2021-2022), Analytical Development | Reveal Email/Phone |
4 | Principal Scientist | Reveal Email/Phone |
5 | Executive Director, Head Translational Medicine | Reveal Email/Phone |
6 | Senior Director/Head Bioinformatics | Reveal Email/Phone |
7 | Senior scientist in DMPK | Reveal Email/Phone |
8 | Manager, Biomarker Operations | Reveal Email/Phone |
9 | Senior Director, Clinical Sciences | Reveal Email/Phone |
10 | VP, Head Regulatory Affairs and Quality Assurance | Reveal Email/Phone |
Repare Therapeutics News
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the...
For Repare Therapeutics Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the...
Repare Therapeutics, a St-Laurent, Quebec, Canada and Cambridge, MA-based precision oncology company targeting specific vulnerabilities of tumors in genetically defined patient populations, completed a US$82.5m Series B financing. The round was led by Cowen Healthcare Investments joined by new ...
Other Companies in Montreal
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $65.3M | 181 | 39% | N/A |
#2 | $40.8M | 181 | 7% | N/A |
#3 | $36.6M | 182 | -3% | N/A |
#4 | $28.4M | 183 | -56% | N/A |
#5 | $48.9M | 183 | 9% | N/A |